Cargando…
Manipulation of Hydrocortisone Tablets Leads to Iatrogenic Cushing Syndrome in a 6-Year-Old Girl With CAH
Currently there are no commercially available hydrocortisone formulations for the treatment of children with congenital adrenal hyperplasia (CAH) that allow for smaller doses (0.1-1.25 mg) and incremental adjustments needed to control excess androgen production and avoid the negative effects of over...
Autores principales: | Al-Rayess, Heba, Fleissner, Kristin, Jaber, Mu’taz, Brundage, Richard C, Sarafoglou, Kyriakie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417883/ https://www.ncbi.nlm.nih.gov/pubmed/32803093 http://dx.doi.org/10.1210/jendso/bvaa091 |
Ejemplares similares
-
Bone Age Maturation and Growth Outcomes in Young Children with CAH Treated with Hydrocortisone Suspension
por: Al-Rayess, Heba, et al.
Publicado: (2021) -
Application of Deep Neural Networks as a Prescreening Tool to Assign Individualized Absorption Models in Pharmacokinetic Analysis
por: Jaber, Mutaz M., et al.
Publicado: (2021) -
Individualized Absorption Models in Population Pharmacokinetic Analyses
por: Jaber, Mutaz M., et al.
Publicado: (2020) -
Case Report: Anastrozole as a monotherapy for pre-pubertal children with non-classic congenital adrenal hyperplasia
por: Liu, Sandy C., et al.
Publicado: (2023) -
Tildacerfont for the Treatment of Patients With Classic Congenital Adrenal Hyperplasia: Results From a 12-Week Phase 2 Clinical Trial in Adults With Classic CAH
por: Auchus, Richard Joseph, et al.
Publicado: (2021)